Table 1. Open in new tab Clinical and...

Characteristic	NK-LGLL (N = 47)	Diminished CD56 group	Normal CD56 group	P value (diminished CD56 group vs normal CD56 group)
Median follow-up [min; max]-month	56.2 [6.7;112.3]	45.8 [6.7; 112.3]	56.4 [12.8; 107.2]	.678
Age at diagnosis-years [min; max]	52 [23; 82]	53 [25; 82]	52 [23; 70]	.522
Gender Male	31/47 (66.0%)	25/28 (89.3%)	6/19 (31.6%)	<.001
Median LGL [min; max]- × 10⁹/L	3.7 [0.04;16.9]	0.9 [0.04; 10.4]	7.6 [0.2; 16.9]	<.001
Need for treatment	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
Symptoms at first visit	29/47 (61.7%)	26/28 (92.9%)	3/9 (15.8%)	<.001
HB <120 g/L	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
HB <90 g/L	18/47 (38.3%)	18/28 (64.3%)	0/19 (0.0%)	<.001
ANC <1.5 × 10⁹/L	19/47 (40.4%)	19/28 (67.9%)	0/19 (0.0%)	<.001
ANC <0.5 × 10⁹/L	2/47 (4.3%)	2/28 (7.1%)	0/19 (0.0%)	.350
PLTs <100 × 10⁹/L	6/47 (12.8%)	5/28 (17.9%)	1/19 (5.3%)	.410
Splenomegaly	14/47 (29.8%)	12/28 (42.9%)	2/19 (10.5%)	.024
ECOG-PS				.105
0	34/47 (72.3%)	17/28 (60.7%)	17/19 (89.5%)
1	10/47 (21.7%)	9/28 (32.1%)	1/19 (5.3%)
2	3/47 (6.5%)	2/28 (7.1%)	1/19 (5.3%)
Autoimmune diseases	7/47 (14.9%)	6/28 (21.4%)	1/19 (5.3%)	.267
PRCA	6/43 (14.0%)	6/26 (23.1%)	0/17 (0.0%)	.092
Secondary primary malignancies	2/47 (4.3%)	0/28 (0.0%)	2/19 (10.5%)	.158
LDH increased	13/42 (31.0%)	11/24 (45.8%)	2/18 (11.1%)	.016
CD2 expression	41/41 (100.0%)
CD3 expression	0/47 (0.0%)
CD8 expression	11/45 (24.5%)	4/24 (14.3%)	7/17 (41.2%)	.093
CD16 expression	37/47 (78.7%)	24/28 (85.7%)	13/19 (68.4%)	.290
CD56 expression
Positive	22/47 (46.8%)
Partial positive	8/47 (17.0%)
Negative	17/47 (36.2%)
CD56 MIF
Bright or moderate	19/22 (86.4%)
Dim	3/22 (13.6%)
CD57 expression	27/43 (62.8%)	14/27 (51.9%)	13/16 (81.3%)	.101
CD94 expression	30/38 (78.9%)	14/21 (66.7%)	16/17 (94.1%)	.096
CD161 expression	12/38 (31.6%)	12/22 (54.5%)	0/16 (0.0%)	<.001
Perforin	35/41 (85.4%)	22/25 (88.0%)	13/16 (81.3%)	.886
Granzyme B	33/41 (80.5%)	21/25 (84.0%)	12/16 (75.0%)	.760
KIR expression				.832
CD158a/b/e/f/i negative	23/37 (62.2%)	14/22 (63.6%)	9/15 (60.0%)
Restrictive expression	14/37 (37.8%)	8/22 (36.4%)	6/15 (40.0%)
CD158i	10/37 (27.0%)	7/22 (31.8%)	3/15 (20.0%)
CD158a	3/37 (8.1%)	2/22 (9.1%)	1/15 (6.7%)
CD158b	2/37 (5.4%)	0/22 (0.0%)	2/15(13.3%)
STAT3 mutation	13/32 (40.6%)	13/21 (61.9%)	0/11 (0.0%)	.003
STAT5B mutation	0/32 (0.0%)
LGL in bone marrow [min; max] %	21.1 [2.4; 51.1]	17.3 [2.4; 47.2]	22.8 [6.2; 51.1]	.135
Bone marrow fibrosis				.006
0	10/42 (23.8%)	2/26 (7.7%)	8/16 (50.0%)
1	30/42 (71.4%)	22/26 (84.6%)	8/16 (50.0%)
2	2/42 (4.8%)	2/26 (7.7%)	0/16 (0.0%)

Characteristic

NK-LGLL (N = 47)

Diminished CD56 group

Normal CD56 group

P value (diminished CD56 group vs normal CD56 group)

(N = 28)

(N = 19)

Median follow-up [min; max]-month

56.2 [6.7;112.3]

45.8 [6.7; 112.3]

56.4 [12.8; 107.2]

.678

Age at diagnosis-years [min; max]

52 [23; 82]

53 [25; 82]

52 [23; 70]

.522

Gender Male

31/47 (66.0%)

25/28 (89.3%)

6/19 (31.6%)

<.001

Median LGL [min; max]- × 10⁹/L

3.7 [0.04;16.9]

0.9 [0.04; 10.4]

7.6 [0.2; 16.9]

<.001

Need for treatment

27/47 (57.4%)

24/28 (85.7%)

3/19 (15.8%)

<.001

Symptoms at first visit

29/47 (61.7%)

26/28 (92.9%)

3/9 (15.8%)

<.001

HB <120 g/L

27/47 (57.4%)

24/28 (85.7%)

3/19 (15.8%)

<.001

HB <90 g/L

18/47 (38.3%)

18/28 (64.3%)

0/19 (0.0%)

<.001

ANC <1.5 × 10⁹/L

19/47 (40.4%)

19/28 (67.9%)

0/19 (0.0%)

<.001

ANC <0.5 × 10⁹/L

2/47 (4.3%)

2/28 (7.1%)

0/19 (0.0%)

.350

PLTs <100 × 10⁹/L

6/47 (12.8%)

5/28 (17.9%)

1/19 (5.3%)

.410

Splenomegaly

14/47 (29.8%)

12/28 (42.9%)

2/19 (10.5%)

.024

ECOG-PS

.105

34/47 (72.3%)

17/28 (60.7%)

17/19 (89.5%)

10/47 (21.7%)

9/28 (32.1%)

1/19 (5.3%)

3/47 (6.5%)

2/28 (7.1%)

1/19 (5.3%)

Autoimmune diseases

7/47 (14.9%)

6/28 (21.4%)

1/19 (5.3%)

.267

PRCA

6/43 (14.0%)

6/26 (23.1%)

0/17 (0.0%)

.092

Secondary primary malignancies

2/47 (4.3%)

0/28 (0.0%)

2/19 (10.5%)

.158

LDH increased

13/42 (31.0%)

11/24 (45.8%)

2/18 (11.1%)

.016

CD2 expression

41/41 (100.0%)

CD3 expression

0/47 (0.0%)

CD8 expression

11/45 (24.5%)

4/24 (14.3%)

7/17 (41.2%)

.093

CD16 expression

37/47 (78.7%)

24/28 (85.7%)

13/19 (68.4%)

.290

CD56 expression

Positive

22/47 (46.8%)

Partial positive

8/47 (17.0%)

Negative

17/47 (36.2%)

CD56 MIF

Bright or moderate

19/22 (86.4%)

Dim

3/22 (13.6%)

CD57 expression

27/43 (62.8%)

14/27 (51.9%)

13/16 (81.3%)

.101

CD94 expression

30/38 (78.9%)

14/21 (66.7%)

16/17 (94.1%)

.096

CD161 expression

12/38 (31.6%)

12/22 (54.5%)

0/16 (0.0%)

<.001

Perforin

35/41 (85.4%)

22/25 (88.0%)

13/16 (81.3%)

.886

Granzyme B

33/41 (80.5%)

21/25 (84.0%)

12/16 (75.0%)

.760

KIR expression

.832

CD158a/b/e/f/i negative

23/37 (62.2%)

14/22 (63.6%)

9/15 (60.0%)

Restrictive expression

14/37 (37.8%)

8/22 (36.4%)

6/15 (40.0%)

CD158i

10/37 (27.0%)

7/22 (31.8%)

3/15 (20.0%)

CD158a

3/37 (8.1%)

2/22 (9.1%)

1/15 (6.7%)

CD158b

2/37 (5.4%)

0/22 (0.0%)

2/15(13.3%)

STAT3 mutation

13/32 (40.6%)

13/21 (61.9%)

0/11 (0.0%)

.003

STAT5B mutation

0/32 (0.0%)

LGL in bone marrow [min; max] %

21.1 [2.4; 51.1]

17.3 [2.4; 47.2]

22.8 [6.2; 51.1]

.135

Bone marrow fibrosis

.006

10/42 (23.8%)

2/26 (7.7%)

8/16 (50.0%)

30/42 (71.4%)

22/26 (84.6%)

8/16 (50.0%)

2/42 (4.8%)

2/26 (7.7%)

0/16 (0.0%)

Characteristic	NK-LGLL (N = 47)	Diminished CD56 group	Normal CD56 group	P value (diminished CD56 group vs normal CD56 group)
Median follow-up [min; max]-month	56.2 [6.7;112.3]	45.8 [6.7; 112.3]	56.4 [12.8; 107.2]	.678
Age at diagnosis-years [min; max]	52 [23; 82]	53 [25; 82]	52 [23; 70]	.522
Gender Male	31/47 (66.0%)	25/28 (89.3%)	6/19 (31.6%)	<.001
Median LGL [min; max]- × 10⁹/L	3.7 [0.04;16.9]	0.9 [0.04; 10.4]	7.6 [0.2; 16.9]	<.001
Need for treatment	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
Symptoms at first visit	29/47 (61.7%)	26/28 (92.9%)	3/9 (15.8%)	<.001
HB <120 g/L	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
HB <90 g/L	18/47 (38.3%)	18/28 (64.3%)	0/19 (0.0%)	<.001
ANC <1.5 × 10⁹/L	19/47 (40.4%)	19/28 (67.9%)	0/19 (0.0%)	<.001
ANC <0.5 × 10⁹/L	2/47 (4.3%)	2/28 (7.1%)	0/19 (0.0%)	.350
PLTs <100 × 10⁹/L	6/47 (12.8%)	5/28 (17.9%)	1/19 (5.3%)	.410
Splenomegaly	14/47 (29.8%)	12/28 (42.9%)	2/19 (10.5%)	.024
ECOG-PS				.105
0	34/47 (72.3%)	17/28 (60.7%)	17/19 (89.5%)
1	10/47 (21.7%)	9/28 (32.1%)	1/19 (5.3%)
2	3/47 (6.5%)	2/28 (7.1%)	1/19 (5.3%)
Autoimmune diseases	7/47 (14.9%)	6/28 (21.4%)	1/19 (5.3%)	.267
PRCA	6/43 (14.0%)	6/26 (23.1%)	0/17 (0.0%)	.092
Secondary primary malignancies	2/47 (4.3%)	0/28 (0.0%)	2/19 (10.5%)	.158
LDH increased	13/42 (31.0%)	11/24 (45.8%)	2/18 (11.1%)	.016
CD2 expression	41/41 (100.0%)
CD3 expression	0/47 (0.0%)
CD8 expression	11/45 (24.5%)	4/24 (14.3%)	7/17 (41.2%)	.093
CD16 expression	37/47 (78.7%)	24/28 (85.7%)	13/19 (68.4%)	.290
CD56 expression
Positive	22/47 (46.8%)
Partial positive	8/47 (17.0%)
Negative	17/47 (36.2%)
CD56 MIF
Bright or moderate	19/22 (86.4%)
Dim	3/22 (13.6%)
CD57 expression	27/43 (62.8%)	14/27 (51.9%)	13/16 (81.3%)	.101
CD94 expression	30/38 (78.9%)	14/21 (66.7%)	16/17 (94.1%)	.096
CD161 expression	12/38 (31.6%)	12/22 (54.5%)	0/16 (0.0%)	<.001
Perforin	35/41 (85.4%)	22/25 (88.0%)	13/16 (81.3%)	.886
Granzyme B	33/41 (80.5%)	21/25 (84.0%)	12/16 (75.0%)	.760
KIR expression				.832
CD158a/b/e/f/i negative	23/37 (62.2%)	14/22 (63.6%)	9/15 (60.0%)
Restrictive expression	14/37 (37.8%)	8/22 (36.4%)	6/15 (40.0%)
CD158i	10/37 (27.0%)	7/22 (31.8%)	3/15 (20.0%)
CD158a	3/37 (8.1%)	2/22 (9.1%)	1/15 (6.7%)
CD158b	2/37 (5.4%)	0/22 (0.0%)	2/15(13.3%)
STAT3 mutation	13/32 (40.6%)	13/21 (61.9%)	0/11 (0.0%)	.003
STAT5B mutation	0/32 (0.0%)
LGL in bone marrow [min; max] %	21.1 [2.4; 51.1]	17.3 [2.4; 47.2]	22.8 [6.2; 51.1]	.135
Bone marrow fibrosis				.006
0	10/42 (23.8%)	2/26 (7.7%)	8/16 (50.0%)
1	30/42 (71.4%)	22/26 (84.6%)	8/16 (50.0%)
2	2/42 (4.8%)	2/26 (7.7%)	0/16 (0.0%)

Characteristic

NK-LGLL (N = 47)

Diminished CD56 group

Normal CD56 group

P value (diminished CD56 group vs normal CD56 group)

(N = 28)

(N = 19)

Median follow-up [min; max]-month

56.2 [6.7;112.3]

45.8 [6.7; 112.3]

56.4 [12.8; 107.2]

.678

Age at diagnosis-years [min; max]

52 [23; 82]

53 [25; 82]

52 [23; 70]

.522

Gender Male

31/47 (66.0%)

25/28 (89.3%)

6/19 (31.6%)

<.001

Median LGL [min; max]- × 10⁹/L

3.7 [0.04;16.9]

0.9 [0.04; 10.4]

7.6 [0.2; 16.9]

<.001

Need for treatment

27/47 (57.4%)

24/28 (85.7%)

3/19 (15.8%)

<.001

Symptoms at first visit

29/47 (61.7%)

26/28 (92.9%)

3/9 (15.8%)

<.001

HB <120 g/L

27/47 (57.4%)

24/28 (85.7%)

3/19 (15.8%)

<.001

HB <90 g/L

18/47 (38.3%)

18/28 (64.3%)

0/19 (0.0%)

<.001

ANC <1.5 × 10⁹/L

19/47 (40.4%)

19/28 (67.9%)

0/19 (0.0%)

<.001

ANC <0.5 × 10⁹/L

2/47 (4.3%)

2/28 (7.1%)

0/19 (0.0%)

.350

PLTs <100 × 10⁹/L

6/47 (12.8%)

5/28 (17.9%)

1/19 (5.3%)

.410

Splenomegaly

14/47 (29.8%)

12/28 (42.9%)

2/19 (10.5%)

.024

ECOG-PS

.105

34/47 (72.3%)

17/28 (60.7%)

17/19 (89.5%)

10/47 (21.7%)

9/28 (32.1%)

1/19 (5.3%)

3/47 (6.5%)

2/28 (7.1%)

1/19 (5.3%)

Autoimmune diseases

7/47 (14.9%)

6/28 (21.4%)

1/19 (5.3%)

.267

PRCA

6/43 (14.0%)

6/26 (23.1%)

0/17 (0.0%)

.092

Secondary primary malignancies

2/47 (4.3%)

0/28 (0.0%)

2/19 (10.5%)

.158

LDH increased

13/42 (31.0%)

11/24 (45.8%)

2/18 (11.1%)

.016

CD2 expression

41/41 (100.0%)

CD3 expression

0/47 (0.0%)

CD8 expression

11/45 (24.5%)

4/24 (14.3%)

7/17 (41.2%)

.093

CD16 expression

37/47 (78.7%)

24/28 (85.7%)

13/19 (68.4%)

.290

CD56 expression

Positive

22/47 (46.8%)

Partial positive

8/47 (17.0%)

Negative

17/47 (36.2%)

CD56 MIF

Bright or moderate

19/22 (86.4%)

Dim

3/22 (13.6%)

CD57 expression

27/43 (62.8%)

14/27 (51.9%)

13/16 (81.3%)

.101

CD94 expression

30/38 (78.9%)

14/21 (66.7%)

16/17 (94.1%)

.096

CD161 expression

12/38 (31.6%)

12/22 (54.5%)

0/16 (0.0%)

<.001

Perforin

35/41 (85.4%)

22/25 (88.0%)

13/16 (81.3%)

.886

Granzyme B

33/41 (80.5%)

21/25 (84.0%)

12/16 (75.0%)

.760

KIR expression

.832

CD158a/b/e/f/i negative

23/37 (62.2%)

14/22 (63.6%)

9/15 (60.0%)

Restrictive expression

14/37 (37.8%)

8/22 (36.4%)

6/15 (40.0%)

CD158i

10/37 (27.0%)

7/22 (31.8%)

3/15 (20.0%)

CD158a

3/37 (8.1%)

2/22 (9.1%)

1/15 (6.7%)

CD158b

2/37 (5.4%)

0/22 (0.0%)

2/15(13.3%)

STAT3 mutation

13/32 (40.6%)

13/21 (61.9%)

0/11 (0.0%)

.003

STAT5B mutation

0/32 (0.0%)

LGL in bone marrow [min; max] %

21.1 [2.4; 51.1]

17.3 [2.4; 47.2]

22.8 [6.2; 51.1]

.135

Bone marrow fibrosis

.006

10/42 (23.8%)

2/26 (7.7%)

8/16 (50.0%)

30/42 (71.4%)

22/26 (84.6%)

8/16 (50.0%)

2/42 (4.8%)

2/26 (7.7%)

0/16 (0.0%)

Table 1.

Open in new tab

Clinical and biological features of 47 NK-LGLL patients and the diminished/ normal CD56 groups

Characteristic	NK-LGLL (N = 47)	Diminished CD56 group	Normal CD56 group	P value (diminished CD56 group vs normal CD56 group)
Characteristic	NK-LGLL (N = 47)	(N = 28)	(N = 19)	P value (diminished CD56 group vs normal CD56 group)
Median follow-up [min; max]-month	56.2 [6.7;112.3]	45.8 [6.7; 112.3]	56.4 [12.8; 107.2]	.678
Age at diagnosis-years [min; max]	52 [23; 82]	53 [25; 82]	52 [23; 70]	.522
Gender Male	31/47 (66.0%)	25/28 (89.3%)	6/19 (31.6%)	<.001
Median LGL [min; max]- × 10⁹/L	3.7 [0.04;16.9]	0.9 [0.04; 10.4]	7.6 [0.2; 16.9]	<.001
Need for treatment	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
Symptoms at first visit	29/47 (61.7%)	26/28 (92.9%)	3/9 (15.8%)	<.001
HB <120 g/L	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
HB <90 g/L	18/47 (38.3%)	18/28 (64.3%)	0/19 (0.0%)	<.001
ANC <1.5 × 10⁹/L	19/47 (40.4%)	19/28 (67.9%)	0/19 (0.0%)	<.001
ANC <0.5 × 10⁹/L	2/47 (4.3%)	2/28 (7.1%)	0/19 (0.0%)	.350
PLTs <100 × 10⁹/L	6/47 (12.8%)	5/28 (17.9%)	1/19 (5.3%)	.410
Splenomegaly	14/47 (29.8%)	12/28 (42.9%)	2/19 (10.5%)	.024
ECOG-PS				.105
0	34/47 (72.3%)	17/28 (60.7%)	17/19 (89.5%)
1	10/47 (21.7%)	9/28 (32.1%)	1/19 (5.3%)
2	3/47 (6.5%)	2/28 (7.1%)	1/19 (5.3%)
Autoimmune diseases	7/47 (14.9%)	6/28 (21.4%)	1/19 (5.3%)	.267
PRCA	6/43 (14.0%)	6/26 (23.1%)	0/17 (0.0%)	.092
Secondary primary malignancies	2/47 (4.3%)	0/28 (0.0%)	2/19 (10.5%)	.158
LDH increased	13/42 (31.0%)	11/24 (45.8%)	2/18 (11.1%)	.016
CD2 expression	41/41 (100.0%)
CD3 expression	0/47 (0.0%)
CD8 expression	11/45 (24.5%)	4/24 (14.3%)	7/17 (41.2%)	.093
CD16 expression	37/47 (78.7%)	24/28 (85.7%)	13/19 (68.4%)	.290
CD56 expression
Positive	22/47 (46.8%)
Partial positive	8/47 (17.0%)
Negative	17/47 (36.2%)
CD56 MIF
Bright or moderate	19/22 (86.4%)
Dim	3/22 (13.6%)
CD57 expression	27/43 (62.8%)	14/27 (51.9%)	13/16 (81.3%)	.101
CD94 expression	30/38 (78.9%)	14/21 (66.7%)	16/17 (94.1%)	.096
CD161 expression	12/38 (31.6%)	12/22 (54.5%)	0/16 (0.0%)	<.001
Perforin	35/41 (85.4%)	22/25 (88.0%)	13/16 (81.3%)	.886
Granzyme B	33/41 (80.5%)	21/25 (84.0%)	12/16 (75.0%)	.760
KIR expression				.832
CD158a/b/e/f/i negative	23/37 (62.2%)	14/22 (63.6%)	9/15 (60.0%)
Restrictive expression	14/37 (37.8%)	8/22 (36.4%)	6/15 (40.0%)
CD158i	10/37 (27.0%)	7/22 (31.8%)	3/15 (20.0%)
CD158a	3/37 (8.1%)	2/22 (9.1%)	1/15 (6.7%)
CD158b	2/37 (5.4%)	0/22 (0.0%)	2/15(13.3%)
STAT3 mutation	13/32 (40.6%)	13/21 (61.9%)	0/11 (0.0%)	.003
STAT5B mutation	0/32 (0.0%)
LGL in bone marrow [min; max] %	21.1 [2.4; 51.1]	17.3 [2.4; 47.2]	22.8 [6.2; 51.1]	.135
Bone marrow fibrosis				.006
0	10/42 (23.8%)	2/26 (7.7%)	8/16 (50.0%)
1	30/42 (71.4%)	22/26 (84.6%)	8/16 (50.0%)
2	2/42 (4.8%)	2/26 (7.7%)	0/16 (0.0%)

Characteristic	NK-LGLL (N = 47)	Diminished CD56 group	Normal CD56 group	P value (diminished CD56 group vs normal CD56 group)
Characteristic	NK-LGLL (N = 47)	(N = 28)	(N = 19)	P value (diminished CD56 group vs normal CD56 group)
Median follow-up [min; max]-month	56.2 [6.7;112.3]	45.8 [6.7; 112.3]	56.4 [12.8; 107.2]	.678
Age at diagnosis-years [min; max]	52 [23; 82]	53 [25; 82]	52 [23; 70]	.522
Gender Male	31/47 (66.0%)	25/28 (89.3%)	6/19 (31.6%)	<.001
Median LGL [min; max]- × 10⁹/L	3.7 [0.04;16.9]	0.9 [0.04; 10.4]	7.6 [0.2; 16.9]	<.001
Need for treatment	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
Symptoms at first visit	29/47 (61.7%)	26/28 (92.9%)	3/9 (15.8%)	<.001
HB <120 g/L	27/47 (57.4%)	24/28 (85.7%)	3/19 (15.8%)	<.001
HB <90 g/L	18/47 (38.3%)	18/28 (64.3%)	0/19 (0.0%)	<.001
ANC <1.5 × 10⁹/L	19/47 (40.4%)	19/28 (67.9%)	0/19 (0.0%)	<.001
ANC <0.5 × 10⁹/L	2/47 (4.3%)	2/28 (7.1%)	0/19 (0.0%)	.350
PLTs <100 × 10⁹/L	6/47 (12.8%)	5/28 (17.9%)	1/19 (5.3%)	.410
Splenomegaly	14/47 (29.8%)	12/28 (42.9%)	2/19 (10.5%)	.024
ECOG-PS				.105
0	34/47 (72.3%)	17/28 (60.7%)	17/19 (89.5%)
1	10/47 (21.7%)	9/28 (32.1%)	1/19 (5.3%)
2	3/47 (6.5%)	2/28 (7.1%)	1/19 (5.3%)
Autoimmune diseases	7/47 (14.9%)	6/28 (21.4%)	1/19 (5.3%)	.267
PRCA	6/43 (14.0%)	6/26 (23.1%)	0/17 (0.0%)	.092
Secondary primary malignancies	2/47 (4.3%)	0/28 (0.0%)	2/19 (10.5%)	.158
LDH increased	13/42 (31.0%)	11/24 (45.8%)	2/18 (11.1%)	.016
CD2 expression	41/41 (100.0%)
CD3 expression	0/47 (0.0%)
CD8 expression	11/45 (24.5%)	4/24 (14.3%)	7/17 (41.2%)	.093
CD16 expression	37/47 (78.7%)	24/28 (85.7%)	13/19 (68.4%)	.290
CD56 expression
Positive	22/47 (46.8%)
Partial positive	8/47 (17.0%)
Negative	17/47 (36.2%)
CD56 MIF
Bright or moderate	19/22 (86.4%)
Dim	3/22 (13.6%)
CD57 expression	27/43 (62.8%)	14/27 (51.9%)	13/16 (81.3%)	.101
CD94 expression	30/38 (78.9%)	14/21 (66.7%)	16/17 (94.1%)	.096
CD161 expression	12/38 (31.6%)	12/22 (54.5%)	0/16 (0.0%)	<.001
Perforin	35/41 (85.4%)	22/25 (88.0%)	13/16 (81.3%)	.886
Granzyme B	33/41 (80.5%)	21/25 (84.0%)	12/16 (75.0%)	.760
KIR expression				.832
CD158a/b/e/f/i negative	23/37 (62.2%)	14/22 (63.6%)	9/15 (60.0%)
Restrictive expression	14/37 (37.8%)	8/22 (36.4%)	6/15 (40.0%)
CD158i	10/37 (27.0%)	7/22 (31.8%)	3/15 (20.0%)
CD158a	3/37 (8.1%)	2/22 (9.1%)	1/15 (6.7%)
CD158b	2/37 (5.4%)	0/22 (0.0%)	2/15(13.3%)
STAT3 mutation	13/32 (40.6%)	13/21 (61.9%)	0/11 (0.0%)	.003
STAT5B mutation	0/32 (0.0%)
LGL in bone marrow [min; max] %	21.1 [2.4; 51.1]	17.3 [2.4; 47.2]	22.8 [6.2; 51.1]	.135
Bone marrow fibrosis				.006
0	10/42 (23.8%)	2/26 (7.7%)	8/16 (50.0%)
1	30/42 (71.4%)	22/26 (84.6%)	8/16 (50.0%)
2	2/42 (4.8%)	2/26 (7.7%)	0/16 (0.0%)

Abbreviations: ANC, absolute neutrophil count; ECOG-PS, Eastern Cooperative Oncology Group performance status; HB, hemoglobin;KIR, Ig-like NK receptors; LGL, large granular lymphocyte; PLT, platelet; PRCA, pure red blood cell aplastic anemia.

This Feature Is Available To Subscribers Only